Their increased expression of hypoxia-inducible factor 1-alpha (HIF-1α) allows CAFs to survive and modulate hypoxic environments, further stimulating NSCLC therapy resistance (Chen et al., 2021). Here, HIF1A is linked to non-small cell lung carcinoma.